Overview

  • Product nameAnti-GFAP antibody [GF-02]
    See all GFAP primary antibodies
  • Description
    Mouse monoclonal [GF-02] to GFAP
  • SpecificityThis antibody exclusively reacts with intact GFAP molecules.
  • Tested applicationsSuitable for: IHC-P, IHC-Fr, WB, ICC/IFmore details
  • Species reactivity
    Reacts with: Rat, Human, Pig
  • Immunogen

    Pellet of pig brain cold-stable proteins after depolymerization of microtubules (Pig).

Properties

Applications

Our Abpromise guarantee covers the use of ab21837 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P
IHC-Fr
WB
ICC/IF
  • Application notesICC/IF: Use at a concentration of 1 µg/ml.
    IHC-P: Use at an assay dependent dilution.
    IHC-Fr: Use at an assay dependent dilution.
    WB: Use at an assay dependent dilution. Predicted molecular weight: 50 kDa.

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionGFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.
    • Tissue specificityExpressed in cells lacking fibronectin.
    • Involvement in diseaseDefects in GFAP are a cause of Alexander disease (ALEXD) [MIM:203450]. Alexander disease is a rare disorder of the central nervous system. It is a progressive leukoencephalopathy whose hallmark is the widespread accumulation of Rosenthal fibers which are cytoplasmic inclusions in astrocytes. The most common form affects infants and young children, and is characterized by progressive failure of central myelination, usually leading to death usually within the first decade. Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures, and psychomotor retardation. Patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course.
    • Sequence similaritiesBelongs to the intermediate filament family.
    • Post-translational
      modifications
      Phosphorylated by PKN1.
    • Cellular localizationCytoplasm. Associated with intermediate filaments.
    • Information by UniProt
    • Database links
    • Alternative names
      • wu:fb34h11 antibody
      • ALXDRD antibody
      • cb345 antibody
      • etID36982.3 antibody
      • FLJ42474 antibody
      • FLJ45472 antibody
      • GFAP antibody
      • GFAP_HUMAN antibody
      • gfapl antibody
      • Glial fibrillary acidic protein antibody
      • Intermediate filament protein antibody
      • wu:fk42c12 antibody
      • xx:af506734 antibody
      • zgc:110485 antibody
      see all

    Anti-GFAP antibody [GF-02] images

    • ICC/IF image of ab21837 stained PC12 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab21837, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

    References for Anti-GFAP antibody [GF-02] (ab21837)

    ab21837 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab21837.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"